Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend Outlook

  • Regeneron Pharmaceuticals Inc REGN earned $25.80 per share for the second quarter, beating the $17.69 estimate. 
  • It clocked revenue of $5.1 billion, surpassing the analysts' consensus of $3.89 billion and higher than $1.95 billion a year ago, primarily attributable to sales from COVID-19 treatment, REGEN-COV. 
  • Excluding REGEN-COV sales of $2.6 billion, sales increased 22% Y/Y. Regeneron delivered 1.25 million doses of REGEN-COV during the quarter.
  • Q2 Eylea U.S. net sales increased 28% Y/Y to $1.42 billion. 
  • The cost of goods sold increased sharply from $103 million to $539 million, primarily due to the recognition of manufacturing costs of REGEN-COV.
  • The operating income increased from $656.4 million to $3.3 billion. Regeneron generated a free cash flow of $478.2 million.
  • Guidance: For FY21, Regeneron sees an adjusted gross margin of 88%–89%. 
  • It expects R&D costs of $2.65 billion - $2.75 billion lower than the previous guidance of $2.7 billion – $2.85 billion.
  • Price Action: REGN shares are up 2.07% at $592.99 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!